{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:19Z","timestamp":1793018119710,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01943-3","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:04:35Z","timestamp":1791363875000},"page":"5761-5776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme"],"prefix":"10.1007","volume":"16","author":[{"given":"Luis E.","family":"Sanchez-Duenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Cha-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Alicia","family":"Aceves-Villalvazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Guajardo-Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Barrera-Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul A.","family":"Becerra-Cerecedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Barragan Garfias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly A.","family":"Espinoza-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1943_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"key":"1943_CR2","first-page":"397","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1943_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.086","author":"JP Okhovat","year":"2019","unstructured":"Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.086.","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85:162\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1943_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"MA Richard","year":"2018","unstructured":"Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the << OBJECTIFS PEAU >> study. J Eur Acad Dermatol Venereol. 2018;32:1967\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1943_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186:257\u201365.","journal-title":"Br J Dermatol"},{"key":"1943_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874677","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Pan L, Wu Y. Epidemiological trends in alopecia areata at the global, regional, and national levels. Front Immunol. 2022;13:874677.","journal-title":"Front Immunol"},{"key":"1943_CR10","unstructured":"Instituto Mexicano del Seguro Social. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica: Tratamiento de la Alopecia Areata en Adultos (IMSS-695-13). 2013. https:\/\/www.imss.gob.mx\/sites\/all\/statics\/guiasclinicas\/695GRR.pdf. Accessed May\u00a029, 2026."},{"key":"1943_CR11","volume":"10","author":"M Mateos-Haro","year":"2023","unstructured":"Mateos-Haro M, Novoa-Candia M, S\u00e1nchez Vanegas G, et al. Treatments for alopecia areata: a network meta-analysis. Cochrane Database Syst Rev. 2023;10:CD013719.","journal-title":"Cochrane Database Syst Rev"},{"key":"1943_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.36849\/JDD.SF396143","volume":"22","author":"A Tosti","year":"2023","unstructured":"Tosti A. Alopecia areata: the clinician and patient voice. J Drugs Dermatol. 2023;22:967\u201375.","journal-title":"J Drugs Dermatol"},{"key":"1943_CR13","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20:S62-8.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1943_CR14","unstructured":"Litfulo (ritlecitinib). Prescribing information. Pfizer; 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638. Accessed May\u00a029, 2026."},{"key":"1943_CR15","unstructured":"Olumiant (baricitinib). Prescribing information. Eli Lilly and Company; 2022. https:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf. Accessed May\u00a029, 2026.\u00a0"},{"key":"1943_CR16","unstructured":"Sun Pharmaceutical Industries Ltd. U.S. FDA approves LEQSELVI\u2122 (deuruxolitinib), an oral JAK inhibitor for the treatment of severe alopecia areata. 2024. https:\/\/sunpharma.com\/wp-content\/uploads\/2024\/07\/Sunpharma-LEQSELVI-Approval-Scenario-Press-Release.pdf. Accessed May\u00a029, 2026."},{"key":"1943_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13555-022-00845-4","volume":"13","author":"MM Vel\u00e1squez-Lopera","year":"2023","unstructured":"Vel\u00e1squez-Lopera MM, Hern\u00e1ndez N, Jansen AM, et al. Alopecia areata in Latin America: where are we and where are we going? Dermatol Ther. 2023;13:95\u2013114.","journal-title":"Dermatol Ther"},{"key":"1943_CR18","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39:1707\u201315.","journal-title":"Curr Med Res Opin"},{"key":"1943_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24:3063\u201372.","journal-title":"Curr Med Res Opin"},{"key":"1943_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6:e010352.","journal-title":"BMJ Open"},{"key":"1943_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2000;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1943_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"1943_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-021-00648-z","volume":"12","author":"KW Wyrwich","year":"2022","unstructured":"Wyrwich KW, Winnette R, Bender R, et al. Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther. 2022;12:149\u201366.","journal-title":"Dermatol Ther"},{"key":"1943_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02737863","volume":"5","author":"MM Chren","year":"2001","unstructured":"Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105\u201310.","journal-title":"J Cutan Med Surg"},{"key":"1943_CR25","first-page":"426","volume":"28","author":"A Mostaghimi","year":"2022","unstructured":"Mostaghimi A, Gandhi K, Done N, et al. All-cause health care resource utilization and costs among adults with alopecia areata: a retrospective claims database study in the United States. J Manag Care Spec Pharm. 2022;28:426\u201334.","journal-title":"J Manag Care Spec Pharm"},{"key":"1943_CR26","doi-asserted-by":"publisher","first-page":"adv12445","DOI":"10.2340\/actadv.v103.12445","volume":"103","author":"N Done","year":"2023","unstructured":"Done N, Bartolome L, Swallow E, et al. Real-world treatment patterns among patients with alopecia areata in the USA: a retrospective claims analysis. Acta Derm Venereol. 2023;103:adv12445.","journal-title":"Acta Derm Venereol"},{"key":"1943_CR27","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1007\/s12325-022-02338-4","volume":"39","author":"M Fridman","year":"2022","unstructured":"Fridman M, Ray M, Gandhi K, Shy ME, Mostaghimi A. Treatment patterns and treatment satisfaction among adults with alopecia areata in the United States. Adv Ther. 2022;39:5504\u201313.","journal-title":"Adv Ther"},{"key":"1943_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","volume":"159","author":"A Mostaghimi","year":"2023","unstructured":"Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 2023;159:411\u20138.","journal-title":"JAMA Dermatol"},{"key":"1943_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000497166","volume":"5","author":"RDC V\u00e9lez-Mu\u00f1iz","year":"2019","unstructured":"V\u00e9lez-Mu\u00f1iz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-S\u00e1nchez MA. Psychological profile and quality of life of patients with alopecia areata. Skin Appendage Disord. 2019;5:293\u20138.","journal-title":"Skin Appendage Disord"},{"key":"1943_CR30","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","volume":"13","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2023","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Blume-Peytavi U, Farrant P, et al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries. Dermatol Ther. 2023;13:3121\u201335.","journal-title":"Dermatol Ther"},{"key":"1943_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1346-8138.16360","volume":"49","author":"E Edson-Heredia","year":"2022","unstructured":"Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: a real-world assessment of severity and burden in Japan. J Dermatol. 2022;49:575\u201383.","journal-title":"J Dermatol"},{"key":"1943_CR32","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s13555-024-01280-3","volume":"14","author":"P Anderson","year":"2024","unstructured":"Anderson P, Piercy J, Austin J, et al. Alopecia areata treatment patterns and satisfaction: results of a real-world cross-sectional survey in Europe. Dermatol Ther. 2024;14:3243\u201358.","journal-title":"Dermatol Ther"},{"key":"1943_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/1346-8138.16615","volume":"50","author":"E Campos-Alberto","year":"2023","unstructured":"Campos-Alberto E, Hirose T, Napatalung L, Ohyama M. Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database. J Dermatol. 2023;50:37\u201345.","journal-title":"J Dermatol"},{"key":"1943_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.abd.2024.10.001","volume":"100","author":"PM Ramos","year":"2025","unstructured":"Ramos PM, Anzai A, Duque-Estrada B, et al. II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata. An Bras Dermatol. 2025;100:328\u201341.","journal-title":"An Bras Dermatol"},{"key":"1943_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","volume":"192","author":"MJ Harries","year":"2024","unstructured":"Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2024;192:190\u2013205.","journal-title":"Br J Dermatol"},{"key":"1943_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR37","unstructured":"European Pharmaceutical Market Research Association. Code of Conduct\/AER. 2025. https:\/\/www.ephmra.org\/code-conduct-aer. Accessed May\u00a029, 2026."},{"key":"1943_CR38","unstructured":"Office of the National Coordinator for Health IT. Health Information Technology Act. 2009. https:\/\/healthit.gov\/wp-content\/uploads\/2025\/06\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed May\u00a029, 2026."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01943-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:04:46Z","timestamp":1793016286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01943-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01943-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ashley S. Cha-Silva and Samantha K. Kurosky are employees of Pfizer Inc and own stock\/stock options in Pfizer Inc. Veronica J. Guajardo-Barron, Raul A. Becerra-Cerecedo, and Jorge Alberto Barragan Garfias are employees of Pfizer Mexico and own stock\/stock options in Pfizer Inc. Peter Anderson and William Jones are employees of Adelphi Real World, Bollington, UK. Nelly A. Espinoza-Gonzalez has received honoraria and has served as a speaker and advisory board member for Galderma, Eli Lilly, AbbVie, UCB, Johnson & Johnson, L\u2019Or\u00e9al, and Sun Pharma. Luis E. Sanchez-Duenas, Martha Alicia Aceves-Villalvazo, and Carlos A. Barrera-Ochoa declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A complete description of the methods of the survey has been previously published and validated [\n                      \n                      \u2013\n                      \n                      ]. Using a checkbox, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and deidentified before receipt. Data collection was undertaken in line with European Pharmaceutical Market Research Association guidelines [\n                      \n                      ], and as such, it does not require ethics committee approval. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ].","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}